Tablet and capsule-format research products.

Oral-format research compounds include AMPK activators, ERR agonists, mitochondrial uncouplers, and lipotropic blend tablets studied in preclinical research models. The Nexus catalog includes 5 oral-format research compounds — examples: BAM15, SLU-PP-332, SLU-PP-332 + BAM15 blend, Lipo-C FAT BLASTER blend, Lipo-C FOCUS blend. Supplied for in-vitro research use only.

Oral tablet and capsule research products use different record and format assumptions than vial-format peptide materials. Nexus keeps these products in a separate category so researchers do not apply vial-specific preparation or documentation fields to tablets and capsules.

This category includes BAM15, SLU-PP-332, SLU-PP-332 + BAM15, Lipo-C Fat Blaster Blend, and Lipo-C Focus Blend. Product pages show format-specific catalog information and variant data.

The oral-format category is structured around product presentation and handling rather than a single pathway. This prevents vial-specific copy, reconstitution recommendations, and solvent cross-sells from appearing where they do not belong.

Nexus provides format-appropriate catalog facts: product identity, variant price, published variant options, and lot/COA context where available. Each blend and standalone compound remains a separate record.

Nexus avoids applying vial-format assumptions to oral-format products. Product pages keep SKU, published price, variant options, and current lot-specific certificate status separate for each record.

Compounds in this category are oral-format research compounds rather than peptides — supplied as research tablets for laboratory bioavailability research and small-molecule pharmacology research. Common research applications include BAM15 research on mitochondrial uncoupler pharmacology, SLU-PP-332 research on estrogen-related receptor (ERR) agonism, and lipotropic blend research using methionine + inositol + choline (MIC) tablet formats.

The five oral compounds span three mechanism types: mitochondrial uncouplers (BAM15), ERR agonists (SLU-PP-332), and lipotropic blend tablets (Lipo-C fat-blaster blend, Lipo-C focus blend, plus the pre-mixed SLU-PP-332 + BAM15 blend). The category groups compounds primarily by format (oral tablets) rather than by mechanism; mechanism-family categorization places these compounds in Mitochondrial & Energy mechanism family.

BAM15, SLU-PP-332, and the SLU-PP-332 + BAM15 blend must be treated as distinct catalog and analytical records. The existence of a blend record does not make standalone compounds interchangeable or recommend combining them. AICAR appears in a separate category and should be evaluated independently through its own identity and lot documentation.

Analytical methods vary by compound, format, and named lot. A finalized lot record publishes only the methods, fields, and results present in its source document. A pending certificate state exposes no assay values; no category-level method panel, purity threshold, or release conclusion is implied.